# S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00124579** · PHASE2 · TERMINATED · sponsor: **SWOG Cancer Research Network** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** bortezomib
- **DRUG:** dexamethasone
- **DRUG:** thalidomide

## Key facts

- **NCT ID:** NCT00124579
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2008-06
- **Final completion:** 2010-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00124579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00124579, "S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00124579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*